89Bio Has Initiated The ENTRUST Phase 3 Trial Evaluating The Efficacy, Safety And Tolerability Of Pegozafermin In Patients With Severe Hypertriglyceridemia
Portfolio Pulse from Benzinga Newsdesk
89Bio has initiated the ENTRUST Phase 3 trial to evaluate the efficacy, safety, and tolerability of Pegozafermin in patients with severe hypertriglyceridemia.
May 23, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
89Bio's initiation of the ENTRUST Phase 3 trial for Pegozafermin may positively impact the company's stock in the short term.
The initiation of the ENTRUST Phase 3 trial for Pegozafermin is a significant milestone for 89Bio. Positive results from the trial could lead to regulatory approval and potential market expansion, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100